Previous 10 | Next 10 |
Plus Therapeutics. (NASDAQ: PSTV ) +63% in-licenses novel oncology candidates. More news on: Plus Therapeutics, Inc., Bellerophon Therapeutics, Inc., Owens & Minor, Inc., Stocks on the move, , Read more ...
The government's $2 trillion emergency relief package caused shares to skyrocket this week; however, the helicopter-Ben style package may inadequately address mid-term economic instability. If so, then this week's rapid run-up could be a short-term sugar high that wears off in April once disma...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”), one of the largest U.S.-based generics manufacturers, and the State of Texas today announced that they are responding to the national COVID-19 health emergency. Amneal has donated 1,000,000 hydr...
In a note, UBS reports that India's Directorate General of Foreign Trade has instituted a moratorium on the export of hydroxychloroquine, a malaria drug in high demand for the treatment of severely ill COVID-19 patients, although the fulfillment of orders placed before the ban will be allowe...
Plenty of stocks have cratered in recent weeks as COVID-19 overtook headlines and our way of life. However, amid the coronavirus chaos, buying opportunities have emerged for those bold enough to act. Here are three drug stocks that could provide a handsome payoff. Image source: Gett...
Waitr Holdings (NASDAQ: WTRH ) +51% on expanding into Grocery Delivery. More news on: Waitr Holdings Inc., Innate Pharma S.A., DCP Midstream, LP, Stocks on the move, Read more ...
Amneal Pharmaceuticals (NYSE: AMRX) announced on Friday that it would be ramping up production of its malaria drug, hydroxychloroquine sulfate, for potential use in treating COVID-19 patient symptoms. The company estimates that it will be able to manufacture around 20 million tablets of the ...
Despite what President Donald Trump said at a White House briefing on Thursday, the Food and Drug Administration (FDA) hasn't approved chloroquine and its less-potent-but-safer offspring, hydrochloroquine, to treat COVID-19 , the disease caused by the new coronavirus. "Normally the FDA would t...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”), one of the largest U.S.-based generics manufacturers, today announced that it is responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sul...
Bellerophon Therapeutics (NASDAQ: BLPH ) +472% on FDA nod for emergency use of INOpulse for Covid-19. More news on: Bellerophon Therapeutics, Inc., Rand Capital, GenMark Diagnostics, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...